Show simple item record

dc.contributor.authorSanchez-Laorden, Bertaen_GB
dc.contributor.authorViros, Amayaen_GB
dc.contributor.authorMarais, Richarden_GB
dc.date.accessioned2013-07-08T15:01:10Z
dc.date.available2013-07-08T15:01:10Z
dc.date.issued2013-06-10
dc.identifier.citationMind the IQGAP. 2013, 23 (6):715-7 Cancer Cellen_GB
dc.identifier.issn1878-3686
dc.identifier.pmid23763998
dc.identifier.doi10.1016/j.ccr.2013.05.017
dc.identifier.urihttp://hdl.handle.net/10541/295470
dc.description.abstractThe scaffold protein IQGAP1 regulates cell signaling through the RAF/MEK/ERK pathway. Recent data show that cancer cells in which the RAF/MEK/ERK pathway is activated are particularly sensitive to the disruption of IQGAP1 function. IQGAP drugs may be particularly effective in tumors that develop resistance to existing pathway drugs.
dc.language.isoenen
dc.rightsArchived with thanks to Cancer cellen_GB
dc.titleMind the IQGAP.en
dc.typeArticleen
dc.contributor.departmentMolecular Oncology Group, The Paterson Institute for Cancer Research, Manchester M20 4, UK.en_GB
dc.identifier.journalCancer Cellen_GB
html.description.abstractThe scaffold protein IQGAP1 regulates cell signaling through the RAF/MEK/ERK pathway. Recent data show that cancer cells in which the RAF/MEK/ERK pathway is activated are particularly sensitive to the disruption of IQGAP1 function. IQGAP drugs may be particularly effective in tumors that develop resistance to existing pathway drugs.


Files in this item

This item appears in the following Collection(s)

Show simple item record